biostudies-literatureUnknown78Koscielniak E<h4>Background</h4>Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end of standard therapy in patients with high-risk rhabdomyosarcoma and STS.<h4>Methods</h4>CWS-2007-HR was a multicentre, open-label, randomised controlled, phase 3 trial done at 87 centers in 5 countries. Eligible patients were those aged 6 months to 21 years with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring in unfavourable sites with unfavourable age (≥10 years) and/or tumour size (>5 cm); all non-metastatic alveolar rhabdomyosarcoma and those with any non-metastatic rhabdomyosarcoma with nodal involvement. A further group was also eligible: patEClinicalMedicine102957https://www.ebi.ac.uk/biostudies/studies/S-EPMC11648192biostudies-literatureMaintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial.PMC11648192Muller HLKoscielniak EScheer MBlank BBielack SKlingebiel TBehnisch WSchmid IBoos JBlattmann CZimmermann MTeichert von Luttichau IHallmen EFrohlich BNiggli Fvon Kalle TLadenstein RHandgretinger RSparber-Sauer MLjungman GVokuhl CKazanowska BfalseMaintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial.<h4>Background</h4>Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end of standard therapy in patients with high-risk rhabdomyosarcoma and STS.<h4>Methods</h4>CWS-2007-HR was a multicentre, open-label, randomised controlled, phase 3 trial done at 87 centers in 5 countries. Eligible patients were those aged 6 months to 21 years with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring in unfavourable sites with unfavourable age (≥10 years) and/or tumour size (>5 cm); all non-metastatic alveolar rhabdomyosarcoma and those with any non-metastatic rhabdomyosarcoma with nodal involvement. A further group was also eligible: pat2024-01-01T00:00:00Z2024 Dec2026-06-02T11:20:18.598Z2025-04-04T01:54:59.326ZS-EPMC116481923968743110.1016/j.eclinm.2024.102957